# Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis

> **NCT07246759** · — · NOT_YET_RECRUITING · sponsor: **OncoHost Ltd.** · enrollment: 600 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer (NSCLC)
- Melanoma (Skin Cancer)
- Triple Negative Breast Cancer (TNBC)
- RCC, Renal Cell Cancer
- HNSCC

## Interventions

- **OTHER:** Blood sample collection

## Key facts

- **NCT ID:** NCT07246759
- **Lead sponsor:** OncoHost Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-15
- **Primary completion:** 2027-09-30
- **Final completion:** 2028-05-30
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2025-11-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07246759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07246759, "Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07246759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*